tldrdailynews.com logo
Tag

Real World Evidence

All articles tagged with #real world evidence

Higher semaglutide doses linked to fewer neuropsychiatric events, beyond weight loss
health1 month ago

Higher semaglutide doses linked to fewer neuropsychiatric events, beyond weight loss

An observational real-world study of 63,215 patients with preexisting neuropsychiatric conditions found that initiating semaglutide was associated with broadly lower neuropsychiatric event risk over two years compared with metformin, SGLT2 inhibitors, or DPP-4 inhibitors. Within the semaglutide group, higher attained doses during the first two years predicted a lower incidence of neuropsychiatric events in the following two years, independent of weight loss. Analyses used de-identified, federated electronic health record data and did not require IRB approval.

via Nature|
#glp-1-receptor-agonist#health#neuropsychiatric-outcomes
Big Real-World Study Finds Hair-Loss Drugs Do Not Increase Heart Disease Risk
health5 months ago

Big Real-World Study Finds Hair-Loss Drugs Do Not Increase Heart Disease Risk

A retrospective TriNetX study of 24,424 androgenetic alopecia patients on finasteride or dutasteride found no increased risk of composite cardiovascular disease or most individual events over 1–5 years; atrial fibrillation risk was lower at 5 years, with other outcomes not significantly different after correction. Limitations include potential confounding and uncertain adherence, but results support CV safety of these drugs in appropriately selected patients.

via Medscape|
#androgenetic-alopecia#cardiovascular-disease#dutasteride
FDA approves leucovorin for ultra-rare CFD-FOLR1 subset without trial
health7 months ago

FDA approves leucovorin for ultra-rare CFD-FOLR1 subset without trial

The FDA updated the leucovorin label to treat cerebral folate deficiency caused by FOLR1 mutations (CFD-FOLR1), a ultrarare condition linked to autism features, approving the drug based on published case reports and mechanistic rationale rather than a randomized trial. The decision narrows the target population to CFD-FOLR1 after reviewers found the highest-quality data in this subgroup; the move relies on real-world evidence and a plausible mechanism pathway. GSK will stop manufacturing Wellcovorin, but generics exist and importation is allowed; broader autism use remains controversial and calls for more research.

via Fierce Pharma|
#cfd-folr1#fda#health
FDA Adopts One-Pivotal-Trial Path for Drug Approvals
health7 months ago

FDA Adopts One-Pivotal-Trial Path for Drug Approvals

The FDA will default to approving drugs based on a single well-controlled pivotal trial, while allowing supporting confirmatory evidence such as mechanistic data, related indications, animal models, or real-world data. The move, framed by FDA leaders as a shift from an outdated ‘two-trial dogma,’ aims to speed development and cut costs, but has drawn criticism from some policymakers and former FDA officials who warn it could weaken patient protections. The policy preserves discretion to require additional studies in certain cases, and reactions are mixed among analysts and industry figures, with Pazdur expressing concerns before his retirement.

via BioSpace|
#clinical-trials#confirmatory-evidence#fda-approvals